High antigenicity of intraperitoneal insulin infusion via implantable devices: preliminary rat studies.
Intraperitoneal insulin infusion of Genapol stabilized insulin via implantable devices significantly improves diabetes control and hypoglycemia frequency in type 1 diabetes while it increases insulin antibody levels. Causes for this particular antigenicity remain unknown. The role of insulin modifications occurring in the reservoir on the antigenicity observed was assessed by comparing the antigenicities of the insulin coming from the vial or from the pump reservoir. Rats were injected intraperitoneally with insulin sampled either from a vial (group 1) or from a pump reservoir during a refill of a clinical trial (group 2). Two control groups, one without insulin, the second one receiving a mixture of silicone and insulin were also studied. Human insulin antibody levels were assessed by RIA 10 days after 4 weekly immunizations. AIA levels were higher in group 1 compared to group 2 (P = 0.003 for the first experiment, P = 0.04 in the second experiment). The increased antigenicity of the insulin sampled from the implanted pump might be due to the insulin modifications occurring during the storage in the device. Insulin aggregates could be involved in this antigenicity since they are known to be antigenic and their concentration was shown to be related to the amplitude of the antigenic response.
Department of Endocrinology and Diabetes, University Hospital, Strasbourg, France. Nathalie.Jeandidier@chru-strasbourg.fr
N
N
Jeandidier
S
S
Boullu
E
E
Delatte
R
R
Sapin
J
J
Steibel
P
P
Meyer
C
C
Uhl
M
M
Pinget
D000818:Animals; D001672:Biocompatible Materials; D005260:Female; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000276:immunology*; D007074:Immunoglobulin G / Q000032:analysis; D007328:Insulin / Q000008:administration & dosage* / Q000276:immunology*; D007330:Insulin Antibodies / Q000097:blood*; D007332:Insulin Infusion Systems; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012828:Silicones
D001672:Biocompatible Materials; D007004:Hypoglycemic Agents; D007074:Immunoglobulin G; D007328:Insulin; D007330:Insulin Antibodies; D012828:Silicones